Michael Rogers has been appointed chief financial officer at Acorda Therapeutics, responsible for the company’s finance and investor relations departments. Also, David Lawrence, M.B.A., who previously served as CFO, has been appointed chief of business operations, responsible for technical operations/manufacturing, project management, IT, and facilities management.
“I’m delighted to welcome Mike Rogers to Acorda’s senior management team. Mike has a record of success as CFO at both commercial- and development-stage biotechnology companies, as well as a background in investment banking,” said Ron Cohen, M.D., Acorda’s president and chief executive officer. “Mike’s strategic insight and broad experience will help us capitalize on opportunities to expand Acorda’s business and continue to deliver shareholder value.”
Mr. Rogers has 22 years of experience in the biopharmaceutical industry. Most recently, he served as executive vice president and chief financial officer of BG Medicine, Inc., where he led the company’s successful IPO in 2011 and assisted in the launch of the company’s first cardiovascular product. Prior to that, Mr. Rogers served as the chief financial officer of Indevus Pharmaceuticals for 10 years until the company’s sale to Endo Pharmaceuticals.
Commenting on Mr. Lawrence’s new role as chief of business operations at Acorda, Dr. Cohen said, “Acorda is now at a stage that requires focused leadership of our business operations. Dave has been a key contributor to building the Company over the last 15 years, and we are fortunate to continue to benefit from his capabilities as he expands his role within Acorda.”